Fixing Gene Therapy Access With AI | How Genoplex Is Helping Patients Get Treated Faster
Many people who could benefit from cutting-edge gene and cell therapies never actually reach a treatment center. That delay isn’t just frustrating—it can cost lives.
In this episode, I’m joined by Christopher Leidli, founder and CEO of Genoplex.ai. Chris brings decades of experience in molecular biology and biotech, including work with giants like Amgen, J&J, and Bayer. We get into why access to advanced therapies is broken, how Genoplex.ai uses smart tech to speed things up, and what it actually takes to match patients with the treatments they need, before it’s too late. We also talk about health equity, the provider burden, and why faxes are still somehow a thing in 2025.
Chris also breaks down what gene and cell therapies really are and how they’ve evolved from the early days of biotech into highly personalized, often one-time treatments. He talks through the massive logistical challenges that stop patients from getting access, from outdated hospital workflows to specialist referral gaps.
Gene therapy can’t change lives if people can’t reach it. Hit play to learn how Genoplex is helping patients finally get the treatments they deserve, on time.
Specifically, this episode highlights the following themes:
- Why so few patients actually access gene and cell therapies
- How Genoplex.ai streamlines the referral and intake process
- Challenges in health equity, provider workflow, and global access
Links from this episode:
- Get to know more about Steven Swan: https://www.linkedin.com/in/swangroup
- Know more about Chris Leidli: https://www.linkedin.com/in/biotechguru
- Learn more about Genoplex.ai: https://www.genoplex.ai
==== Time Stamps ====
00:00 – Introduction
01:12 – About Christopher Leidli
03:31 – What’s the difference between gene and cell therapy?
05:15 – How many therapies are FDA-approved?
07:42 – Global access issues and health equity
10:13 – Why patients aren’t reaching treatment centers
12:17 – What Genoplex.ai actually does
16:02 – Improving provider workflows and referrals
18:10 – Expanding treatment indications beyond blood cancer
24:54 – Why clinical trial matching isn’t enough
29:30 – The administrative burden at treatment centers
31:23 – How the treatment center qualification process works
